Market research
INDV.LSE Indivior PLC
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 1049.3093
- Dividend yield
- Not available
- Beta
- 0.26
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- GB00BN4HT335
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 1049.3093
- Dividend yield
- Not available
- Beta
- 0.26
About
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the INDV.LSE discussion.
5 years, 5 months ago
Indivior PLC is currently in a long term uptrend where the price is trading 23.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Indivior PLC's total revenue rose by 39.1% to $185M since the same quarter in the previous year.
Its net income has increased by 76.4% to $-13M since the same quarter in the previous year.
Finally, its free cash flow fell by 302.8% to $-73M since the same quarter in the previous year.
Based on the above factors, Indivior PLC gets an overall score of 4/5.